atrasentan has been researched along with Bone Cancer in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, M; Lara, PN; Mack, PC; Moinpour, CM; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Taneja, SS | 1 |
| Ely, B; Gertz, E; Goldkorn, A; Hussain, M; Lara, PN; Mack, PC; Quinn, DI; Tangen, C; Thompson, IM; Twardowski, PW; Van Loan, MD; Vogelzang, NJ | 1 |
| Carducci, MA; Dutcher, JP; Liu, G; Manola, J; Nair, SG; Rousey, S; Wilding, G | 1 |
| Danke, JR; Drake, JM; Henry, MD | 1 |
| Abdulkadir, SA; Roh, M | 1 |
| Garber, K | 1 |
| Carducci, MA; Lassiter, LK | 1 |
| Ghilardi, JR; Lindsay, TH; Luger, NM; Mantyh, PW; Peters, CM; Pomonis, JD; Sevcik, MA | 1 |
| Carducci, M; Jimeno, A | 1 |
| Clines, GA; Guise, TA | 1 |
| Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR | 1 |
| Carducci, MA; Jimeno, A | 1 |
| Banerjee, S; Bonfil, D; Che, M; Cher, M; Hussain, M; Saliganan, A; Sarkar, FH; Wang, Z | 1 |
| Abrahamsson, PA; Carducci, MA; Dearnaley, DP; Isaacson, JD; Nelson, JB; North, SA; Saad, F; Schulman, CC; Sleep, DJ | 1 |
| Nelson, JB | 1 |
4 review(s) available for atrasentan and Bone Cancer
| Article | Year |
|---|---|
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2003 |
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Topics: Apoptosis; Atrasentan; Bone Neoplasms; Clinical Trials as Topic; Disease Progression; Endothelins; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines | 2005 |
Mechanisms and treatment for bone metastases.
Topics: Animals; Atrasentan; Bone Neoplasms; Cell Adhesion Molecules; Cytokines; Diphosphonates; Endothelin-1; Female; Gene Expression Regulation, Neoplastic; Humans; Hypercalcemia; Immunotherapy; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Nude; Neoplasm Proteins; Osteoblasts; Osteolysis; Pain; Pain Management; Pyrrolidines; Xenograft Model Antitumor Assays | 2004 |
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Endothelin Receptor Antagonists; Female; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 2006 |
5 trial(s) available for atrasentan and Bone Cancer
| Article | Year |
|---|---|
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Survival Rate; Taxoids | 2013 |
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Collagen Type I; Disease-Free Survival; Docetaxel; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; ROC Curve; Taxoids; Treatment Failure | 2014 |
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).
Topics: Adult; Aged; Aged, 80 and over; Atrasentan; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Endothelin Receptor Antagonists; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Pyrrolidines; Treatment Outcome | 2015 |
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid | 2006 |
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines | 2007 |
8 other study(ies) available for atrasentan and Bone Cancer
| Article | Year |
|---|---|
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
Bone-specific growth inhibition of prostate cancer metastasis by atrasentan.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Male; Mice; Prostatic Neoplasms; Pyrrolidines; Random Allocation; Xenograft Model Antitumor Assays | 2010 |
Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?
Topics: Animals; Atrasentan; Bone Neoplasms; Disease Models, Animal; Endothelin Receptor Antagonists; Humans; Male; Mice; Molecular Targeted Therapy; Prostatic Neoplasms; Pyrrolidines | 2010 |
Why it hurts: researchers seek mechanisms of cancer pain.
Topics: Acidosis; Analgesics; Animals; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Glycoproteins; Humans; Ion Channels; Neoplasms; Osteoprotegerin; Pain; Pyrrolidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |
Endothelin and the tumorigenic component of bone cancer pain.
Topics: Analysis of Variance; Animals; Atrasentan; Behavior, Animal; Bone Neoplasms; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dynorphins; Endothelin Receptor Antagonists; Endothelin-1; Ganglia, Spinal; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Mice; Mice, Inbred Strains; Pain; Pain Measurement; Pyrrolidines; Receptors, Endothelin; Sarcoma; Sciatic Nerve; Time Factors | 2004 |
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; DNA, Neoplasm; Docetaxel; Drug Synergism; Endothelin A Receptor Antagonists; Humans; Male; Mice; Mice, SCID; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Atrasentan prolongs time to progression in prostate cancer patients.
Topics: Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Drug Administration Schedule; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Bone Resorption; Disease Progression; Endothelin Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |